Drug Profile
Obinutuzumab - Roche
Alternative Names: Afutuzumab; GA-101; GAZYVA; Gazyva; Gazyvaro; huMAB(CD20) - Roche; R-7159; RG 7195; RG-7159; RG7159-7; RO-5072759Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator GLYCART Biotechnology
- Developer Biogen Idec; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Lymphoma Academic Research Organisation; Mario Negri Institute for Pharmacological Research; Mayo Clinic; Nippon Shinyaku; OHSU Knight Cancer Institute; Pharmacyclics; Polish Myeloma Consortium; Roche; Thomas Jefferson University; University of Heidelberg; University of Leeds
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death inhibitors; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Phase III Diffuse large B cell lymphoma; Glomerulonephritis; Lupus nephritis; Nephrotic syndrome; Systemic lupus erythematosus
- Phase II CNS cancer; Focal segmental glomerulosclerosis; Graft-versus-host disease; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Discontinued Primary biliary cirrhosis
Most Recent Events
- 02 Jan 2024 Roche plans a phase II GLORIFY trial for Richter's syndrome (Combination Therapy, First-line therapy) in France (NCT06186648)
- 10 Nov 2023 Updated adverse events and efficacy data from the phase II NOBILITY trial in Lupus nephritis presented at the ACR Convergence 2023 (ACR-ARP-2023)
- 28 Sep 2023 Infinity Pharmaceuticals files for Chapter 11 bankruptcy and has been dissolved